Neuroendocrine Liver Metastases
- 21 Downloads
Available guidelines in NEN liver metastases acknowledge the role of loco-regional therapies in NENs with liver-predominant disease not responding to systemic therapy, to control tumor growth and symptoms . However, there is a substantial lack of large-scale prospective studies and randomized clinical trials in the setting of loco-regional therapies.
These two studies provide data on large series of patients with NEN of any origin and grade treated either with transarterial chemoembolization (TACE)  or with Y90-Radioembolization (RE) . Both studies included a substantial number of patients with intrahepatic tumor load > 50%, extrahepatic disease, functioning lesions and heavily pretreated disease. Despite these unfavorable (and heterogeneous) baseline characteristics, both RE and TACE...
Compliance with Ethical Standards
Conflict of interest
Irene Bargellini received honoraria for speaking at symposia from Bayer, Terumo Europe, Sirtex and BTG and a research grant from BTG. The other authors declare that they have no conflicts of interest.
- 3.Pavel M, O’Toole D, Costa F, et al. Vienna consensus conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85. https://doi.org/10.1159/000443167.CrossRefGoogle Scholar